Last reviewed · How we verify
HB-01
HB-01 is a small molecule that targets the SIRT6 protein to modulate cellular metabolism.
HB-01 is a small molecule that targets the SIRT6 protein to modulate cellular metabolism. Used for Type 2 diabetes.
At a glance
| Generic name | HB-01 |
|---|---|
| Also known as | Active Drug |
| Sponsor | Honeybrains Biotech LLC |
| Drug class | SIRT6 inhibitor |
| Target | SIRT6 |
| Modality | Small molecule |
| Therapeutic area | Metabolic disorders |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SIRT6, HB-01 aims to increase the expression of genes involved in cellular metabolism, potentially leading to improved glucose regulation and reduced inflammation.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Safety and Efficacy of HB-1 for Panic Disorder (PHASE2)
- Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine (PHASE2)
- Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults (PHASE1, PHASE2)
- Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB-01 CI brief — competitive landscape report
- HB-01 updates RSS · CI watch RSS
- Honeybrains Biotech LLC portfolio CI